U.S. FDA approves Acadia's genetic Rett syndrome drug

Argentina Noticias Noticias

U.S. FDA approves Acadia's genetic Rett syndrome drug
Argentina Últimas Noticias,Argentina Titulares
  • 📰 Reuters
  • ⏱ Reading Time:
  • 36 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 97%

The U.S. Food and Drug Administration approved Acadia Pharmaceuticals Inc's drug for the treatment of Rett syndrome, a genetic brain disorder, the company said on Friday, making it the first approved drug for the condition.

Acadia said it plans to make the drug available to patients by the end of April. It did not disclose details of the price.

Acadia forecasts sales of Nuplazid - its only drug on the market - of between $520 and $550 million this year, above analysts' median expectations of $532.8 million, according to Refinitiv data. With the drugmaker facing a loss of exclusivity for Nuplazid in 2028, investors have pinned their hopes on a successful trofinetide launch.

Rett's syndrome is a rare neurodevelopmental condition that occurs primarily in girls. According to government estimates, it affects fewer than 50,000 people in the U.S.Acadia's drug acts as an artificial form of the insulin-like growth factor IGF-1 and helps reduces inflammation in the nervous tissue as well as aid in the transmission of nerve impulses.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

Reuters /  🏆 2. in US

Argentina Últimas Noticias, Argentina Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

FDA approves new nasal spray to treat migraine headaches in adultsFDA approves new nasal spray to treat migraine headaches in adultsThe U.S. Food and Drug Administration approved a new nasal spray as a rapid treatment for migraine pain in adults, Pfizer said.
Leer más »

FDA approves new nasal spray to treat migraine headaches in adults, Pfizer says | CNNFDA approves new nasal spray to treat migraine headaches in adults, Pfizer says | CNNThe FDA has approved a new nasal spray as a rapid treatment for migraine pain in adults. The spray may relieve pain and other migraine symptoms as soon as 15 minutes after use, drugmaker Pfizer says.
Leer más »

FDA Flags Shortage of Medication Used to Treat Breathing ConditionsFDA Flags Shortage of Medication Used to Treat Breathing ConditionsThe US health regulator said on Wednesday that it is working to address a shortage of a particular form of albuterol, a medication used to treat breathing conditions, as its sole manufacturer Akorn has stopped production.
Leer más »

Albuterol Shortage Challenges Hospitals Treating Patients With Breathing ProblemsAlbuterol Shortage Challenges Hospitals Treating Patients With Breathing ProblemsHospitals are running out of a liquid form of albuterol, a medication used to treat people with breathing problems, weeks after the only maker of the product declared bankruptcy
Leer más »

FDA sets national mammogram standards to protect women with dense breastsFDA sets national mammogram standards to protect women with dense breastsMammogram providers will be required to inform women with dense breast tissue that their cancer screenings may be difficult to interpret and recommend consulting their doctors about the need for additional tests, the Food and Drug Administration announced.
Leer más »

Dietary supplement recalled for claims it can cure COVID 19: FDADietary supplement recalled for claims it can cure COVID 19: FDANatural Solutions Foundation issued a recall for its Dr Rima Recommends Nano Silver 10ppm dietary supplement after federal officials say it falsely claims it can sure COVID-19.
Leer más »



Render Time: 2025-04-08 05:54:26